Argen-X BV, of Breda, the Netherlands, reported it has advanced its CD-70 targeting ARGX-110 into the safety and efficacy expansion part of its Phase Ib study to further investigate its safety in CD70-positive cancer patients, and to evaluate efficacy in order to select the indications to be studied in Phase II clinical development.